{"id":14293,"date":"2026-06-02T01:05:00","date_gmt":"2026-06-01T23:05:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=08d032fa5735ea65198b1a1f188b4e0d"},"modified":"2026-06-02T01:05:00","modified_gmt":"2026-06-01T23:05:00","slug":"contineum-therapeutics-to-present-at-the-2026-goldman-sachs-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=14293","title":{"rendered":"Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference"},"content":{"rendered":"<p>SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced that management is scheduled to present at the 2026 Goldman Sachs Global Healthcare Conference on Tuesday, June 9th at 1:20 p.m. ET.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260601133303\/en\/2332155\/5\/CTNM_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260601133303\/en\/2332155\/22\/CTNM_Logo.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260601133303\/en\/2332155\/5\/CTNM_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260601133303\/en\/2332155\/21\/CTNM_Logo.jpg\" \/><\/a><p>\nAn audio webcast of the fireside chat can be accessed on the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.contineum-tx.com%2F&amp;esheet=54543093&amp;newsitemid=20260601133303&amp;lan=en-US&amp;anchor=Investors&amp;index=1&amp;md5=9cff2aa984f66d9b35e2f96ad2862df3\" rel=\"nofollow\" shape=\"rect\">Investors<\/a> section of Contineum\u2019s website. A webcast replay will also be available.<\/p><p>\n<b>About Contineum Therapeutics<\/b><\/p><p>\nContineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&amp;I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder. For more information, please visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.contineum-tx.com&amp;esheet=54543093&amp;newsitemid=20260601133303&amp;lan=en-US&amp;anchor=www.contineum-tx.com&amp;index=2&amp;md5=9754cc152de5b90c22cf9b29bda06c45\" rel=\"nofollow\" shape=\"rect\">www.contineum-tx.com<\/a>.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nSteve Kunszabo\n<br\/>Contineum Therapeutics\n<br\/>Senior Director, Investor Relations &amp; Corporate Communications\n<br\/>858-649-1158\n<br\/><a  href=\"mailto:skunszabo@contineum-tx.com\" rel=\"nofollow\" shape=\"rect\">skunszabo@contineum-tx.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&amp;I)&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-14293","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14293"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14293\/revisions"}],"predecessor-version":[{"id":14294,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14293\/revisions\/14294"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}